Invitae Corp., of San Francisco, is launching a new program called SMA Identified with Cambridge, Mass.-based Biogen Inc. to offer free genetic testing to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA). Biogen, which sells SMA treatment Spinraza (nusinersen), is supporting the program financially, but won't receive patient information.